News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boston Scientific Corporation (BSX) Jumps into Renal Denervation Race



6/12/2012 9:02:48 AM

Incoming Boston Scientific CEO Michael Mahoney details the med-tech titan's 2012-2013 development and regulatory approval timelines for its up-and-coming business regions, including for its newly acquired Cameron Health subcutaneous implantable defibrillators and its bronchial thermoplasty business. Boston Scientific's (NYSE:BSX) got a busy road ahead, with regulatory approvals and market launches in the works for products in some of its hottest business divisions. During a conference held in Marlborough, Mass., today, incoming CEO Michael Mahoney – currently listed as president – detailed the outlook for 7 of the company's up-and-coming divisions, including for the newly acquired Cameron Health subcutaneous ICD and the highly competitive renal denervation market.

Read at MassDevice


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES